First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors

Clinical Cancer Research

Volumn 18, Issue 17, 2012, Pages 4806-4819

  Martinez Garcia, Maria ^a,b   Banerji, Udai ^e   Albanell, Joan ^a,b,c   Bahleda, Rastilav ^f,g   Dolly, Saoirse ^e   Kraeber Bodéré, Françoise ^h   Rojo, Federico ^b,d   Routier, Emilie ^f,g   Guarin, Ernesto ⁱ   Xu, Zhi Xin ^j   Rueger, Ruediger ^k   Tessier, Jean J L ⁱ   Shochat, Eliezer ⁱ   Blotner, Steve ^j   Naegelen, Valerie Meresse ⁱ   Soria, Jean Charles ^f,g  

^a HOSPITAL DEL MAR   (Spain)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d 28400 Madrid   (Spain)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g UNIVERSITÉ PARIS SACLAY   (France)

^h CENTRE RENÉ GAUDUCHEAU   (France)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

^j HOFFMANN LA ROCHE INC   (United States)

^k ROCHE DIAGNOSTICS GMBH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN INHIBITOR; RAF PROTEIN; RO 5126766; UNCLASSIFIED DRUG;

ACNE; ADRENAL CANCER; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLURRED VISION; BREAST CANCER; CANCER TISSUE; CAPILLARY LEAK SYNDROME; COLORECTAL CANCER; CONFUSION; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; ECZEMA; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ERYTHEMA; ESOPHAGUS CANCER; EWING SARCOMA; EYELID EDEMA; FEBRILE NEUTROPENIA; FEMALE; FOLLICULITIS; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; LUNG CANCER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; MYOPATHY; NAUSEA; OVARY CANCER; PANCREAS CANCER; PARONYCHIA; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSORIASIS; PUSTULE; RETINA DETACHMENT; RETINA MACULA EDEMA; SIDE EFFECT; SINGLE DRUG DOSE; SKIN BIOPSY; SKIN CARCINOMA; SOLID TUMOR; STOMATITIS; TESTIS CANCER; TUMOR BIOPSY; UTERUS CANCER; VESICULAR RASH;

ADMINISTRATION, ORAL; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAP KINASE KINASE KINASES; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; TREATMENT OUTCOME;

EID: 84865749357     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0742     Document Type: Article

References (44)

1. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007;26:3279-90.
2. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 2005;6:322-7.
3. Pearson G, Robinson F, Beers GT, Xu BE, Karandikar M, Berman K, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22:153-83.
4. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999;18:813-22.
5. Bos JL. Ras Oncogenes in Human Cancer: A Review. Cancer Res 1989;49:4682-9.
6. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003;95:625-7.
7. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-54.
8. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003;63:4561-7.
9. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26:2139-46.
10. Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007;6:2209-19.
11. Gilmartin AG, Kusnierz AM, Sutton D, Moss KG, Thompson CS, Weber BL, et al. GSK1120212 is a novel Mek inhibitor demonstrating sustained inhibition of ERK phosphorylation and selective inhibition of BRaf and RAS mutant cells in preclinical models. Eur J Cancer Suppl 2008;6:178.
12. Johnston S. XL518, a potent selective orally bioavailable MEK1 inhibitor down regulates the RAS/RAF/MEK/ERK pathway in vivo, resulting in tumor growth inhibition and regression in pre-clinical models. In: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007 Oct 22-26; San Francisco, CA. Philadelphia (PA): AACR; 2007. Abstract nr C209.
13. Lang I, Adenis A, Boer K, Escudero P, Kim T, Valladares M, et al. AZD6244 (ARRY-142886) versus capecitabine (CAP) in patients (pts) with metastatic colorectal cancer (mCRC) who have failed prior chemotherapy. J Clin Oncol 26:20s, 2008 (suppl; abstr 4114).
14. Lorusso P, Krishnamurthi S, Rinehart JR, Nabell L, Croghan G, Varterasian M, et al. A Phase 1-2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer. J Clin Oncol 23:16s, 2005 (suppl; abstr 3011).
15. Miner J, Yu C, Iverson C, Hamatake R, Cheney W, Chapman M, et al. Selective MEK Inhibitor RDEA119 exhibits efficacy in orthotopic hepatoma models and cytostatic potential in multiple cell based models of cancer. Eur J Cancer Suppl 2008;6:181.
16. Schwartz GK, Yazji S, Mendelson DS, Dickson MA, Johnston SH, Wang EW, et al. A phase 1 study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients (pts) with advanced solid tumors. Eur J Cancer 6:120, 2008 (abstr 383).
17. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Lee RJ, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 28:15s, 2010 (suppl; abstr 3534).
18. Kefford R, Arkenau H, Brown MP, Millward M, Infante JR, Long GV, et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 28:15s, 2010 (suppl; abstr 8503).
19. Banerji U, Camidge DR, Verheul HM, Agarwal R, Sarker D, Kaye SB, et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 2010;16:1613-23.
20. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
21. O'Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, et al. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2011;29:2350-6.
22. Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, et al. Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers. J Clin Oncol 2011;29:2357-63.
23. Little AS, Balmanno K, Sale MJ, Newman S, Dry JR, Hampson M, et al. Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells. Sci Signal 2011;4:ra17.
24. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
25. Cichowski K, Janne PA. Drug discovery: inhibitors that activate. Nature 2010;464:358-9.
26. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
27. F. Hoffman-La Roche Ltd. Entry-into-human starting dose. In: Investigator's brochure first version. Basel: F. Hoffman-La Roche Ltd.; 2008.
28. National Cancer Institute Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events, version 3.0. Available from: http://ctep.cancer.gov/protocoldevelopment/electronic-applications/docs/ctcaev3. pdf. 2006.
29. Delord J, Houede N, Awada A, Taamma A, Faivre SJ, Besse-Hammer T, et al. First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors. J Clin Oncol 28:15s, 2010 (suppl; abstr 2504).
30. Lee L, Niu H, Rueger R, Igawa Y, Deutsch J, Ishii N, et al. The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: target suppression using a biomarker. Clin Cancer Res 2009;15:7368-74.
31. Rojo F, Tabernero J, Albanell J, Van CE, Ohtsu A, Doi T, et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 2006;24:4309-16.
32. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773-82.
33. Lorusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 2010;16:1924-37.
34. Thompson DS, Flaherty K, Messersmith W, Harlacker K, Nallapareddy S, Vincent C, et al. A three-part, phase I, dose-escalation study of GSK1120212, a potent MEK inhibitor, administered orally to subjects with solid tumors or lymphoma. J Clin Oncol 27, 2009 (suppl; abstr e14584).
35. Shapiro G, LoRusso P, Kwak E, Cleary J, Musib L, Jones C, et al. Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors. J Clin Oncol 29, 2011 (suppl; abstr 3005).
36. Kurzrock R, Patnaik A, Rosenstein L, Fu S, Papadopoulos K, Smith D, et al. Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795). J Clin Oncol 29, 2011(suppl; abstr 3085).
37. Gore L, Lewis K, Von Hoff D, Weiss G, Ramanathan R, Adjei A, et al. Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer. J Clin Oncol 29, 2011 (suppl; abstr 3007).
38. Infante J, Falchook G, Lawrence D, Weber J, Kefford R, Bendell J, et al. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). J Clin Oncol 29, 2011 (suppl; abstr CRA8503).
39. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004;22:4456-62.
40. Ciuffini L, Castellani L, Salvati E, Galletti S, Falcone G, Alema S. Delineating v-Src downstream effector pathways in transformed myoblasts. Oncogene 2008;27:528-39.
41. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000;351 Pt 2: 289-305.
42. Garcia R, Grindlay J, Rath O, Fee F, Kolch W. Regulation of human myoblast differentiation by PEBP4. EMBO Rep 2009;10:278-84.
43. Lawlor MA, Feng X, Everding DR, Sieger K, Stewart CE, Rotwein P. Dual control of muscle cell survival by distinct growth factor-regulated signaling pathways. Mol Cell Biol 2000;20:3256-65.
44. Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005;23: 5281-93.